Adaptive Biotechnologies Corp - 8-K Filing
Adaptive Biotechnologies issued $345 million in aggregate principal amount of 0% Convertible Senior Notes due 2031, with net proceeds totaling approximately $334.5 million after fees and expenses. The company used $156.9 million from the offering to repay its obligations under a revenue interest purchase agreement with OrbiMed, effectively terminating that arrangement. (Items: 1.01 Entry into a Material Definitive Agreement, 1.02 Item 2, 3.02 Unregistered Sales of Equity Securities, 8.01 Other Events)
Tickers: $ADPT